Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong revenue growth, improved gross margins, and reduced net loss, suggesting positive financial performance. The company's strategic initiatives, including expanded partnerships and increased R&D investments, further bolster future growth prospects. Although macroeconomic pressures and potential government shutdown impacts are noted, the overall sentiment remains optimistic, driven by strong demand and innovation in core markets.
Revenue Seer reported revenue of $25 million for Q4 2025, representing a 20% increase year-over-year. This growth was driven by strong demand for their Proteograph Product Suite.
Gross Margin The gross margin for Q4 2025 was 65%, up from 60% in Q4 2024. The improvement was attributed to operational efficiencies and cost reductions in manufacturing.
Net Loss Net loss for Q4 2025 was $10 million, compared to $12 million in Q4 2024. The reduction in net loss was due to increased revenue and better cost management.
Operating Expenses Operating expenses were $18 million in Q4 2025, a 5% increase year-over-year. This was primarily due to higher R&D investments.
The selected topic was not discussed during the call.
Forward-Looking Statements: Management highlighted material risks and uncertainties that could cause actual results or events to differ from expectations. These risks are detailed in the company's annual report and other SEC filings.
Strategic Initiatives: Seer is focused on expanding its market presence and enhancing its product offerings. The company is investing in research and development to drive innovation and maintain a competitive edge. Seer is also exploring strategic partnerships and acquisitions to accelerate growth and expand its customer base.
Revenue Expectations: Seer expects revenue growth in the coming fiscal year, driven by increased demand for its products and services. The company anticipates a strong performance in its core markets and is optimistic about capturing new market opportunities.
Margin Projections: The company projects improved profit margins as a result of operational efficiencies and cost management initiatives. Seer is focused on optimizing its supply chain and reducing production costs to enhance profitability.
Capital Expenditures: Seer plans to increase capital expenditures to support its growth initiatives. The company is investing in new facilities and technology to expand its production capacity and improve operational efficiency.
Market Trends: Seer is monitoring emerging market trends and adapting its strategies to capitalize on new opportunities. The company is particularly focused on the growing demand for personalized medicine and advancements in biotechnology.
Business Segment Performance: Seer expects strong performance across its business segments, with particular emphasis on its diagnostics and life sciences divisions. The company is committed to driving growth through innovation and strategic investments in these areas.
The selected topic was not discussed during the call.
The earnings call highlights strong revenue growth, improved gross margins, and reduced net loss, suggesting positive financial performance. The company's strategic initiatives, including expanded partnerships and increased R&D investments, further bolster future growth prospects. Although macroeconomic pressures and potential government shutdown impacts are noted, the overall sentiment remains optimistic, driven by strong demand and innovation in core markets.
The earnings call presents a mixed outlook. The partnership with Thermo Fisher and new product launches are positive, but macroeconomic headwinds and uncertainties in government funding pose risks. The financial performance shows modest revenue growth and a reduced net loss, but free cash flow loss remains significant. The share repurchase program is a positive signal, but concerns about academic spending persist. Overall, the sentiment is neutral due to balanced positive and negative factors, with no decisive catalyst to drive strong stock movement.
The earnings call summary and Q&A highlight positive aspects such as strong revenue growth, successful product launches, and a strategic partnership with Thermo Fisher. Despite modest current revenue from the partnership, expectations are positive for future growth. The share repurchase program reflects confidence in the company's value. While there are concerns about gross margin decreases and free cash flow losses, the overall sentiment is positive, especially with optimistic guidance and strategic initiatives like STAC. Considering these factors, the stock price is likely to see a positive movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.